Orexigen Terminates Another Contrave Outcomes Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
A month after losing its big pharma partner, Orexigen gives up on its second cardiovascular outcomes trial, though it promises it will meet FDA's requirement for obesity drug Contrave.